Showing 261 - 280 results of 289 for search '"pancreatic cancer"', query time: 0.09s Refine Results
  1. 261

    Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy by Kahori Seto, Junichi Shoda, Tomohisa Horibe, Eiji Warabi, Masayuki Kohno, Toru Yanagawa, Hiroki Bukawa, Yasuni Nakanuma, Koji Kawakami

    Published 2014-01-01
    “…We previously designed novel IL-4Rα-lytic hybrid peptide composed of binding peptide to IL-4Rα and cell-lytic peptide and reported that the designed IL-4Rα-lytic hybrid peptide exhibited cytotoxic and antitumor activity both in vitro and in vivo against the human pancreatic cancer cells expressing IL-4Rα. Here, we evaluated the antitumor activity of the IL-4Rα-lytic hybrid peptide as a novel molecular targeted therapy for human biliary tract cancer (BTC). …”
    Get full text
    Article
  2. 262
  3. 263

    Elderly Patients with Nondistant Metastatic Pancreatic Head Adenocarcinoma Cannot Benefit from More Radical Surgery by Li Chen, Lanning Jia, Zhigang Tian, Yang Yang, Ke Zhao

    Published 2022-01-01
    “…The incidence of pancreatic cancer continues to rise globally, with pancreatic head cancer accounting for nearly 60–70%. …”
    Get full text
    Article
  4. 264

    Artificial intelligence methods applied to longitudinal data from electronic health records for prediction of cancer: a scoping review by Victoria Moglia, Owen Johnson, Gordon Cook, Marc de Kamps, Lesley Smith

    Published 2025-01-01
    “…The most common cancers predicted in the studies were colorectal (n = 9) and pancreatic cancer (n = 9). 16 studies used feature engineering to represent temporal data, with the most common features representing trends. 18 used deep learning models which take a direct sequential input, most commonly recurrent neural networks, but also including convolutional neural networks and transformers. …”
    Get full text
    Article
  5. 265

    Effects of air pollution on the development and progression of digestive diseases: an umbrella review of systematic reviews and meta-analyses by Haonan Zhao, Xiaojie Zheng, Guo Lin, Xiaomin Wang, Huiyuan Lu, Pengpeng Xie, Siqi Jia, Yiyang Shang, Yan Wang, Pengchu Bai, Xuan Zhang, Ning Tang, Xingshun Qi

    Published 2025-01-01
    “…PM2.5 exposure was significantly associated with liver dysfunction, chronic liver diseases, liver cancer, and colorectal cancer, but not oesophagus cancer, gastric cancer, or pancreatic cancer. Based on very low to moderate quality evidence from meta-analyses, PM2.5 exposure may contribute to the development of some digestive diseases, especially liver diseases.…”
    Get full text
    Article
  6. 266

    Cytotoxic Activity of Bisphosphonic Derivatives Obtained by the Michaelis–Arbuzov or the Pudovik Reaction by Zsuzsanna Szalai, Janka Bednárik, Boldizsár Szigfrid Tóth, Angéla Takács, Szilárd Tekula, László Kőhidai, Konstantin Karaghiosoff, László Drahos, György Keglevich

    Published 2025-01-01
    “…Compounds lacking hydroxy groups showed anti-myeloma activity or limited effect on pancreatic cancer (PANC-1) cells unless substituted with para-trifluoromethyl group. …”
    Get full text
    Article
  7. 267

    Postoperative Ratio of C-Reactive Protein to Albumin as a Predictive Marker in Patients with Crohn’s Disease Undergoing Bowel Resection by Hangfen Zhao, Huaying Liu, Weilin Qi, Wei Liu, Lingna Ye, Qian Cao, Xiaolong Ge, Wei Zhou, Xianfa Wang

    Published 2021-01-01
    “…The ratio of C-reactive protein (CRP) to albumin (CAR) has a significant correlation with postoperative complications and acts as a predictor in patients with pancreatic cancer and colorectal cancer. However, whether the CAR can be used to predict complications in Crohn’s disease (CD) patients after surgery has not yet been reported. …”
    Get full text
    Article
  8. 268

    Diagnostics and treatment of pancreatic exocrine insufficiency: clinical guidelines of the Russian gastroenterological association by V. T. Ivashkin, I. V. Mayev, A. V. Okhlobystin, S. A. Alekseyenko, Ye. V. Beloborodova, Yu. A. Kucheryavy, T. L. Lapina, A. S. Trukhmanov, I. B. Khlynov, M. V. Chikunova, A. A. Sheptulin, O. S. Shifrin

    Published 2018-08-01
    “…This syndrome may develop primarily, due to various pancreatic diseases (chronic pancreatitis, pancreatic cancer, cystic fibrosis etc.), and secondarily, at impaired stimulation of pancreatic secretion or impairment of conditions, necessary for the normal action of pancreatic enzymes. …”
    Get full text
    Article
  9. 269

    A Novel PET Imaging Using 64Cu-Labeled Monoclonal Antibody against Mesothelin Commonly Expressed on Cancer Cells by Kazuko Kobayashi, Takanori Sasaki, Fumiaki Takenaka, Hiromasa Yakushiji, Yoshihiro Fujii, Yoshiro Kishi, Shoichi Kita, Lianhua Shen, Hiromi Kumon, Eiji Matsuura

    Published 2015-01-01
    “…In in vitro and ex vivo immunochemical studies, we demonstrated specificity of 11-25 mAb to membranous MSLN expressed on several pancreatic cancer cells. We showed the accumulation of Alexa Fluor 750-labeled 11-25 mAb in MSLN-expressing tumor xenografts in athymic nude mice. …”
    Get full text
    Article
  10. 270

    High serum CA19-9 predicts severe cholecystitis in calculous cholecystitis patients by Shouwen Wang, Dachen Zhou, Wanjin Chen, Qi Guo, Liujin Hou, Ruolin Wu, Wei Wang, Muhammad Annus Khan, Muhammad Ahmad, Fan Huang, Meijuan Zheng, Guobin Wang, Hongchuan Zhao, Xiaoping Geng, Xiaojun Yu

    Published 2025-01-01
    “…Abstract Background CA19-9 is a classical tumor marker and plays an important role in the diagnosis of biliary and pancreatic cancer. However, a few cases reported that the tumor maker CA19-9 is abnormally elevated in patients with calculous cholecystitis, but the relation between severity of calculous cholecystitis and serum CA19-9 level are still unknown. …”
    Get full text
    Article
  11. 271

    Characterizing immune biomarkers and effector CD8+ T-cell exhaustion in pancreatic adenocarcinoma via single-cell RNA sequencing profiling by Rawaa AlChalabi, Raghda Makia, Semaa A. Shaban, Ahmed AbdulJabbar Suleiman

    Published 2025-01-01
    “…Further clinical studies are necessary to validate the therapeutic potential of these anti-inflammatory drugs in enhancing immune responses in pancreatic cancer.…”
    Get full text
    Article
  12. 272

    An Optimized Liquid Chromatography–Mass Spectrometry Method for Ganglioside Analysis in Cell Lines by Akeem Sanni, Andrew I. Bennett, Yifan Huang, Isabella Gidi, Moyinoluwa Adeniyi, Judith Nwaiwu, Min H. Kang, Michelle E. Keyel, ChongFeng Gao, C. Patrick Reynolds, Brian Haab, Yehia Mechref

    Published 2024-10-01
    “…The optimized method was applied to profile gangliosides in neuroblastoma (COG-N-683), pancreatic cancer (PSN1), breast cancer (MDA-MB-231BR), and brain tumor (CRL-1620) cell lines. …”
    Get full text
    Article
  13. 273

    Diagnostics and treatment of exocrine pancreatic insufficiency: clinical guidelines of the Russian gastroenterological Association by V. T. Ivashkin, I. V. Mayev, A. V. Okhlobystin, S. A. Alekseyenko, Ye. V. Beloborodova, Yu. A. Kucheryavy, T. L. Lapina, A. S. Trukhmanov, I. B. Khlynov, M. V. Chikunova, A. A. Sheptulin, O. S. Shifrin

    Published 2018-08-01
    “…This state can develop primarily, due to various pancreatic diseases (chronic pancreatitis, pancreatic cancer, cystic fibrosis), and secondarily, due to impaired stimulation of pancreatic secretion or non-physiological conditions for activity of digestive enzymes. …”
    Get full text
    Article
  14. 274

    Rhoifolin Suppresses Cell Proliferation and Induces Apoptosis in Hepatocellular Carcinoma Cells In Vitro and In Vivo by Ruolan Chen, Zufa Sabeel, Lu Ying, Youfeng Liang, Rui Guo, Mingxuan Hao, Xiaoyang Chen, Wenjing Zhang, Jian Dong, Yan Liu, Changyuan Yu, Zhao Yang

    Published 2025-01-01
    “…Rhoifolin (ROF), a flavonoid constituent, has previously been shown to suppress the proliferation of breast and pancreatic cancer cells. However, its inhibitory effect on HCC has remained unexplored. …”
    Get full text
    Article
  15. 275

    Dendritic cell maturation is induced by p53-armed oncolytic adenovirus via tumor-derived exosomes enhancing systemic antitumor immunity by Tomoko Ohtani, Shinji Kuroda, Nobuhiko Kanaya, Yoshihiko Kakiuchi, Kento Kumon, Masashi Hashimoto, Chiaki Yagi, Ryoma Sugimoto, Satoru Kikuchi, Shunsuke Kagawa, Hiroshi Tazawa, Yasuo Urata, Toshiyoshi Fujiwara

    Published 2024-11-01
    “…Exosomes (Exo53, Exo301, or Exo702) were isolated from conditioned media of human or murine pancreatic cancer cell lines (Panc-1, MiaPaCa-2, and PAN02) after treatment with Ad-p53, OBP-301, or OBP-702. …”
    Get full text
    Article
  16. 276
  17. 277
  18. 278
  19. 279

    Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy by Yishen Tian, Jingxuan Li, Na Yang, Yang Zhao, Jiancao Zuo, Hang Xiong, Yiwen Pan, Li Xiao, Min Su, Feng Han, Zhixu He, Rong Hu

    Published 2025-04-01
    “…Experimental results demonstrated that this cellular preparation exhibited promising therapeutic effects in both melanoma and pancreatic cancer models. This research provided a novel platform for the synergistic cooperation of various methods in tumor immunotherapy, holding broad application prospects.…”
    Get full text
    Article
  20. 280

    VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1 by Zongfu Pan, Jinming Chen, Tong Xu, Anqi Cai, Bing Han, Ying Li, Ziwen Fang, Dingyi Yu, Shanshan Wang, Junyu Zhou, Yingying Gong, Yulu Che, Xiaozhou Zou, Lei Cheng, Zhuo Tan, Minghua Ge, Ping Huang

    Published 2025-02-01
    “…In our study, we found targeting VSIG4+ TAMs by VSIG4 deficiency or blockade remarkably limited tumor growth and metastasis, especially those derived from anaplastic thyroid cancer (ATC) and pancreatic cancer, two extremely aggressive types. Moreover, the combination of VSIG4 blockade with a BRAF inhibitor synergistically enhanced anti-tumor activity in ATC-tumor bearing mice. …”
    Get full text
    Article